What Researchers Did
Researchers described the use of hyperbaric oxygen therapy (HBOT) combined with immunosuppression to treat acute macular neuroretinopathy (AMN) in two patients with systemic lupus erythematosus (SLE).
What They Found
Both patients, who had AMN associated with SLE and worsened despite high-dose steroids, underwent twelve cycles of HBOT. They experienced immediate functional and anatomical improvements, which were sustained for over one year, with complete resolution of visual field scotoma and no significant retinal thinning.
What This Means for Canadian Patients
This study suggests HBOT might be a beneficial add-on therapy for AMN in SLE patients who do not respond to standard immunosuppression. Canadian patients with similar conditions could potentially benefit from this combined treatment approach to improve visual outcomes.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or patients.
Study Limitations
A significant limitation of this study is its very small sample size, involving only two patients, which limits the generalizability of the findings.